Kornimate/medical-research-clean huggingface dataset:
a longitudinal study of covid-19 positive patients testing nasal swabs and collecting blood samples for research

Conditions: SARS-CoV Infection

Summary: minimal risk research study: 1. comparing polyester nasal swabs and foam nasal swabs to detect sars-cov-2 virus; 2. quantifying the development and trajectory of the disease through clinic visits and blood values.

this work will serve both the everett clinic and broader unitedhealth group patient populations as well as advance the public health emergency response to the community spread of sars-cov-2 virus, especially as the number of cases and deaths continues to rise in many geographies. a recent study conducted at the everett clinic showed that foam nasal swabs were able to detect sars-cov-2 virus at comparable levels to nasopharyngeal (np) swabs. we now look to build off this work by comparing polyester foam swabs, which are more readily available and mass producible, to foam nasal swabs, in their sensitivity for detecting sars-cov-2 virus. we also plan to assess the viability of dry swabbing, where the swab is stored without saline or viral transport media (vtm) at room temperature for four days, to calculate the degradation of the viral sample. finally, we will collect up to 50 ml/visit of blood longitudinally from patients who have previously tested positive for sars-cov-2 at visit one, two, and four weeks following their initial covid-10 diagnosis.the medical professional drawing the blood will determine if the patient is at an increased risk from a blood draw due to underlying conditions such as anemia. in these cases, the amount of blood drawn will be left to the discretion of the medical professional but shall not surpass 10 ml per visit.these longitudinal blood samples will help us gain a better understanding of the trajectory of covid-19 (in terms of both clinical symptomology and viral load) and antibody development. at each visit, nasal swabs and blood samples will be collected, and the blood samples will be stored in a repository for future research.

Eligibility criteria:
inclusion criteria: * existing patient of the everett clinic (i.e., has previously sought care) * tested positive for sars-cov-2 virus (confirmed by rt-pcr) prior to time of enrollment exclusion criteria: * not able to demonstrate understanding of the study * not able to safely travel to the clinic without endangering themselves or risking exposing others to sars-cov-2 * medical history evidencing any of the following * active nosebleed in the past 24 hours * nasal surgery in the past two weeks * chemotherapy treatment with low platelet and low white blood cell counts * acute facial trauma * advanced covid-19 state that would preclude safe and feasible sample collection
dbs for treatment resistant depression

Conditions: Depressive Disorder, Treatment-Resistant

Summary: the purpose of this study is to examine the effects of sub-callosal cingulate (scc) deep brain stimulation (dbs) in patients with treatment resistant depression (trd). the working hypotheses are that long pulse-width dbs applied to the scc region will lead to improvements in trd patients, and specific neuroimaging biomarkers will correlate with response to dbs; the functional recovery will be enhanced with concurrent cognitive behavioural therapy (cbt).

the aim is to collect data on prediction, optimization and augmentation of dbs for trd and develop tools for dbs surgery. it is a biological pilot study designed to provide informative data for future work.

Eligibility criteria:
inclusion criteria: * age 20-70 * diagnosis of major depressive (mdd)or bipolar disorder(bp)determined independently by 2 study psychiatrists * current major depressive episode of \>1 year duration, treatment-resistant (meaning failure to respond to 4 different classes of antidepressants, including augmentation or combination strategies with lithium, atypical antipsychotics, anticonvulsants, antidepressants, evidence-based psychotherapy, cbt, or electroconvulsive treatment despite adequate dosage, duration and compliance) * minimum score of 20 (out of 52) on the 17 item hamilton depression rating scale (hdrs) * resident of alberta, canada, covered by alberta health exclusion criteria: * other axis i psychiatric disorders including schizophrenia, psychosis, active suicidal ideation over previous 6 months * cerebrovascular risk factors, previous stroke, head injury and neurodegenerative disorders, pregnancy, medical and general contraindications for dbs surgery (e.g. cardiac pacemaker/defibrillator) * age \>70 * diabetes

Keywords: major depressive disorder (mdd) bi-polar disorder (bp)
prediction of postpartum hemorrhage with uterine artery doppler measurement

Conditions: Postpartum Hemorrhage

Summary: the aim of the study is to evaluate the uterine artery doppler just before labour in term low risk pregnancies. and to investigate with this measurement if investigators could foreseen the amount of postpartum hemorrhage looking at decreased in the hematocrit values.


Eligibility criteria:
inclusion criteria: * singleton term pregnancies exclusion criteria:the pregnant women who have * polyhydramnios * large for gestational age fetuses * multiple pregnancies * preterm labour * chorioamnionitis * history of atonia or postpartum hemorrhage
discrete hypothermia in the management of traumatic brain injury

Conditions: Severe Traumatic Brain Injury

Summary: the primary goal of this project is to demonstrate the feasibility and clinical benefits of a new rapid treatment for secondary treatment for secondary brain injury called discrete cerebral hypothermia system by coolsystems, inc., berkley, ca. this device induced hypothermia in the adult brain without significant whole body hypothermia. discrete cerebral hypothermia system holds a great potential for protecting the brain from the devastating secondary complications of trauma without the associated deleterious system effects.


Eligibility criteria:
inclusion criteria: * patient is treated for severe traumatic brain injury at grady health system, gcs \< 8 * patient is \>18 years of age * patient requires an intracranial pressure (icp) probe (part of their routine treatment) * patient is able to receive discrete cerebral hypothermia within 48-hours of hospital admission * patient and/or guardian must speak english (in order to ensure proper informed consent) * patient and/or guardian/family must sign an informed consent exclusion criteria: * unwillingness or inability of patient and/or guardian/ family to sign an informed consent * physical placement of cooling cap impedes routine treatment * patient has a core body temperature of 36 degrees c or less at time of assessment

Keywords: traumatic brain injury trauma hypothermia
preventing long term psychiatric disability among those with major burn injuries

Conditions: Stress Disorders, Post-Traumatic; Mood Disorders; Sleep Disorders

Summary: the purpose of this study is to determine whether a newly developed, brief cognitive behavioral intervention, relative to supportive counseling, is effective in reducing acute stress disorder (asd) and preventing post traumatic stress disorder (ptsd) and depression.

importance: burns are painful, life threatening and disfiguring. severe psychological distress, pain and sleep disturbance are among the most common, enduring and disabling of secondary complications, however, no evidence based treatments exists for these complex problems in the acute burn care setting. design: randomized, controlled effectiveness trial, group assignment blinded to baseline status, groups stratified by history of pre-existing psychiatric disorder. objectives. to develop the safety, meaning, activation and resilience training (smart) protocol; to evaluate its short and long-term effectiveness, relative to viable placebo, supportive counseling (sc), in improving key dependent measures (e.g., asd, ptsd), mediators, and, enhancing health and function outcomes. setting: a leading edge, state-dedicated, regional burn center in a major, metropolitan teaching hospital serving diverse residents from large urban settings, small towns and remote rural areas. interventions: smart (focused cognitive-behavioral therapy with training in anxiety management, and treatment with prolonged exposure and cognitive restructuring) will be contrasted with sc (non-directive empathy, warmth, positive regard). primary outcome measures: health (psychological distress, sleep, pain), function (physical, psychological, social), costs (direct and indirect).

Eligibility criteria:
inclusion criteria: * 18 to 70 years old * acute burn injury * exceeding criteria on screening instrument at baseline (in-hospital prior to treatment): acute stress disorder scale (asds score ≥ 37: acute posttrauma distress). exclusion criteria: * age less than 18 or greater than 70 years * presence of a significant cognitive / neurological or psychiatric condition precluding informed consent (e.g., psychosis, acute suicidality) * inability to communicate in english * intubated or sedated

Keywords: behavior therapy randomized controlled trial
evaluation of a binaural spatialization method for hearing aids

Conditions: Sensorineural Hearing Loss

Summary: this study investigates the possible benefits of using binaural spatialization techniques in digital wireless microphone systems for hearing aids. speech intelligibility tests, speaker localization tests and preference tests are performed. the results of a diotic (current rendering) and a binaural (suggested rendering) rendering are compared.

the signal processing laboratory (lts2) of the swiss federal institute of technology (epfl) has developed a new feature of sound rendering in hearing aids. this is a collaboration between epfl and the swiss company phonak communications ag. the new functionality works with the range of roger products from phonak, a new generation of fm systems that use a digital transmission. fm technology refers to a type of wireless system that helps people better understand speech in noisy situations. fm systems commonly work together with a user's hearing aids, although systems are also available for those with otherwise normal hearing (such as people who suffer from apd, adhd etc.). an fm system works like this: the person speaking wears or holds a transmitter microphone, or the transmitter is placed in the middle of the group (picking up speech from all around). using harmless radio waves, the fm system sends speech signal(s) to the listener, who wears a tiny fm receiver behind the ear. the new feature of such systems performs processing of the speaker's speech signal so that it renders information related to their spatial location. this so-called sound "spatialization" is a natural property of the human binaural auditory system, which allows us to localize sounds. however, this sound spatialization is not delivered by the current fm systems. thanks to the new technology from epfl and phonak, it is now possible to include a binaural spatialization of the speech signal in the roger product of phonak hearing devices.

Eligibility criteria:
inclusion criteria * french-native speakers and adults. * normal otoscopy. * no conductive pathology. * normal hearing, or moderate to severe, sloping or flat, symmetrical hearing loss. * user of bilateral phonak hearing aids, for more than 6 months (hearing-impaired only). exclusion criteria: * history of tinnitus or hyperacusis. * visual impairment, after correction with glasses or not. * history of chronic or terminal illness or psychiatric disturbance,. * history of epilepsy or other reactions associated with the proximity to a video screen.
buprenorphine maintenance for opioid addicts - 3

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to evaluate buprenorphine in a medical maintenance model three times a week.


Eligibility criteria:
please contact site for information.

Keywords: opioid-related disorders
daily disposable silicone hydrogel contact lens, stenfilcon a, clinical study

Conditions: Myopia

Summary: clinical evaluation of stenfilcon a compared with narafilcon a and delefilcon a this is a total 120 subject, randomized, open label, bilateral wear, two week crossover study (each lens for 1 week) evaluating the clinical performance of stenfilcon a spherical lenses compared to narafilcon a or delefilcon a spherical lenses.

the aim of this study is to evaluate the clinical performance of stenfilcon a compared with narafilcon a and delefilcon a. the study participants will be allocated to two parallel groups (group 1 and group 2), 60 subjects each, based on the control lenses, narafilcon a and delefilcon a spherical lenses. study groups: group 1: stenfilcon a vs. narafilcon a group 2: stenfilcon a vs. delefilcon a

Eligibility criteria:
inclusion criteria: - a person is eligible for inclusion in the study if he/she: * is over 18 years of age (inclusive) * has had a self-reported visual exam in the last two years * is an adapted daily disposable non-silicone hydrogel spherical contact lens wearer * can achieve best corrected spectacle distance visual acuity of 20/25 or better in each eye. * can achieve a distance visual acuity of 20/30 or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter. * has a cl (contact lens) spherical prescription between - 0.75 and - 8.00 (inclusive) * is willing to comply with the wear schedule. * is willing to comply with the visit schedule exclusion criteria: - a person will be excluded from the study if he/she: * is not a habitual wearer of daily disposable non-silicone hydrogel spherical contact lenses * has a cl prescription outside the range of the inclusion power range * has a spectacle cylinder ≥1.00d of cylinder in either eye. * has a history of not achieving comfortable cl wear (5 days per week; \> 8 hours/day) * has contact lens best corrected distance vision worse than 20/25 in either eye * presence of clinically significant (grade 2-4) anterior segment abnormalities * presence of ocular or systemic disease or need of medications which might interfere with contact lens wear * slit lamp findings that would contraindicate contact lens wear * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea. * has undergone corneal refractive surgery. * is participating in any other type of eye related clinical or research study.
efficacy and safety of a triple eradication scheme for helicobacter pylori based on tegoprazan vs esomeprazole

Conditions: Helicobacter Pylori Infection

Summary: in mexico, quadruple therapy is used to treat helicobacter pylori (h.p.) at the expense of greater adverse effects, costs, and lower adherence to treatment. according to evidence, a competitive potassium channel blocker (p-cab) is non-inferior to a proton pump inhibitor (ppi) and can improve the eradication rate of h.p. while maintaining triple therapy antibiotics (amoxicillin-clarithromycin) without increasing adverse effects, fewer drugs and better adherence to treatment. it is proposed to study the effect of a p-cab in the eradication of h.p. as part of a triple therapy in mexican patients, assuming that the efficacy and safety of a triple therapy of amoxicillin-clarithromycin-tegoprazan will be superior to amoxicillin-clarithromycin-esomeprazole.

160 patients with a diagnosis of h.p. infection with indication for treatment in accordance with the iv mexican consensus on helicobacter pylori, evaluated in the gastroenterology outpatient clinic, will be recruited. participants will be randomized into two groups, one group will receive tegoprazan 50 mg bid, clarithromycin 500 mg bid and amoxicillin 1 gr bid for 14 days and the second group will receive esomeprazole 40 mg bid, clarithromycin 500 mg bid and amoxicillin 1 gr bid for 14 days. through complementary studies, telephone calls and application of questionnaires, adherence to treatment will be evaluated and adverse events will be monitored, and once the treatment period is completed, a breath test will be performed between days 28-42 to verify eradication, thereby evaluating effectiveness.

Eligibility criteria:
inclusion criteria: * first-degree relatives with a history of gastric cancer. * clinical diagnosis of uninvestigated dyspepsia in patients under 50 years of age. * diagnosis of gastric mucosa - aassociated lymphoid tissue (malt) lymphoma. * iron deficiency anemia. * unexplained thrombocytopenic purpura. exclusion criteria: * patients who have social coverage. * previous eradication treatment for helicobacter pylori. * acute upper gastrointestinal bleeding and active gastric and/or duodenal ulcer. * history of surgery that affects gastric acid secretion (vagotomy, gastrointestinal resection). * disorders of gastric acid hypersecretion (zollinger-ellison syndrome). * any serious hematological, cardiovascular, neurological, nephro-urological, hepatic and pulmonary disorders. * pregnancy or lactation. * allergy to any of the study medications.

Keywords: tegoprazan esomeprazole effectiveness safety
does lead burden alter neuropsychological development?

Conditions: Lead Poisoning

Summary: inner city children are at an increased risk for lead overburden. this in turn affects cognitive functioning. however, the underlying neuropsychological effects of lead overburden and its age-specific effects have not been well delineated. this study is part of a larger study on the effects of lead overburden on the development of attention and memory. the larger study is using a multi-model approach to study the effects of lead overburden on these effects including the event-related potential (erp), electrophysiologic measures of attention and memory are studied. every eight months, for a total of three sessions the subjects will complete erp measures of attention and memory which require them to watch various computer images while wearing scalp electrodes recording from 11 sites. it is this test that we are going to be doing on crc. there will be 30 lead overburdened children recruited from the larger study for participation in the erp studies on crc. these 30 children will be matched with 30 children without lead overburden. this portion of the study is important in providing an index of physiological functioning to be used along with behaviorally based measures of attention and memory, and for providing information about the different measures.


Eligibility criteria:
inclusion criteria: * pregnant mothers of the phillips neighborhood in minneapolis, minnesota. subject recruitment will take place in local clinics which serve pregnant women and offspring

Keywords: lead overburden
using biomarkers for diagnosis, risk stratification of post -treatment recurrence and long-term surveillance of lung cancer

Conditions: Lung; Node; Adenocarcinoma of Lung

Summary: this study is an observational study of blood and tissue biomarkers. investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.


Eligibility criteria:
inclusion criteria: * potentially-resectable lung nodule 8-40 mm diameter suspected (no preop diagnosis) of being a clinically node-negative lung cancer \[clinical stage ia-ib (ct1a-t2an0), \<4cm diameter\]. * if surgical resection is recommended, patient will undergo surgery at moffitt cancer center. * if a definite tissue diagnosis is obtained and stereotactic body radiotherapy (sbrt) is the recommended treatment instead of surgery, the sbrt will be delivered at moffitt cancer center. * \>18 years old, male or female. * ecog performance status 0-1. * agree to participate in the follow-up protocol. * any suspected primary lung cancer cell type (except a suspected typical carcinoid tumor, carcinoma in situ or minimally-invasive carcinoma). * ability to understand and the willingness to sign a written, informed consent document. exclusion criteria: * participants who are actively receiving any cancer treatment. * participants with uncontrolled intercurrent illness. * prior lung cancer within 5 years. * current active other major cancer except non-melanoma skin cancer. * patients with pure ground glass opacities (nodules) or hilar masses. * suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma). * metastatic nodule (suspected) in the lung from an extrapulmonary cancer. * patient unable to provide informed consent. * prisoner or incarcerated individual. * for surgical patients, a r1 or r2 resection.

Keywords: biomarkers lung cancer biomarkers
a study to investigate the efficacy and safety of baxdrostat in participants with uncontrolled hypertension on two or more medications including participants with resistant hypertension

Conditions: Uncontrolled Hypertension; Resistant Hypertension

Summary: the purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uhtn or rhtn. the main objective is to compare the difference in sbp change from baseline at week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets.

this is a phase iii, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered qd orally, on the reduction of sbp in approximately 300 participants aged ≥ 18 years with htn (≥ 140 mmhg at screening; ≥ 135 mmhg at randomisation) despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uhtn); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (rhtn).

Eligibility criteria:
inclusion criteria: * male or female participants must be ≥ 18 years old. * mean seated sbp on automated office blood pressure measurement (aobpm) ≥ 140 mmhg at screening. * fulfil at least 1 of the following 2 criteria: 1. uhtn subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the investigator. 2. rhtn subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the investigator. * estimated glomerular filtration rate ≥ 45 ml/min/1.73m2 at screening. * serum potassium (k+) level ≥ 3.5 and \< 5.0 mmol/l at screening.• mean seated sbp on aobpm ≥ 135 mmhg at baseline. exclusion criteria: * mean seated sbp on aobpm ≥ 170 mmhg. * mean seated dbp on aobpm ≥ 105 mmhg. * serum sodium level (na+) \< 135 mmol/l at screening. * has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, cushing's syndrome, aortic coarctation. * nyha functional heart failure class iv at screening.

Keywords: hypertension uncontrolled hypertension resistant hypertension blood pressure baxdrostat cin-107 aldosterone aldosterone synthase